The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | MAIA trial: addition of daratumumab to Rd in newly diagnosed transplant-ineligible MM
Thierry Facon, MD, Claude Huriez Hospital, Lille, France, presents the interim results of the Phase III MAIA trial (NCT02252172), which evaluated the addition of daratumumab to lenalidomide/dexamethasone (D-Rd) vs. Rd alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). The D-Rd regimen significantly reduced the risk of progression or death, with no new safety signals. Combined with the results of the ALCYONE study (D-VMP vs. VMP; NCT02195479), these data support the addition of daratumumab to the standard of care in transplant-ineligible NDMM. This video was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
